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Rectal reduction dose in prostate cancer with inﬂatable spacer system
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Introduction. Prostate cancer is the most common cancer in men. Radiotherapy is one of the treatments of choice for prostate
cancer, but rectal bleeding toxicity is one of its major complications.
Purpose. To assess the safety of a biodegradable rectal balloon spacer and its effectiveness in decreasing rectal dose in prostate
cancer patients treated with radiotherapy.
Methods. Three patients with localized prostate cancer treated with radiotherapy. Prior to treatment with radiation, is implanted a
rectal balloon spacer (BioProtect®). The balloon is made of a co-polymer of poly-lactide acid and epsilon-caprolactone. It degrades
after 6 months of placement. The implant is performed in the operating room, under spinal anesthesia, with the patient in
lithotomy position. The device is implanted transperineally under transrectal ultrasound (TRUS) guidance. The biodegradable
balloon is placed between the prostate and the anterior rectal wall. Once positioned is inﬂated with saline solution, increasing
the distance prostate–rectum, 16mm on average. Planning CT was performed before implantation and after it. The treatment
plan is calculated in both CT scans, prescription dose 76Gy.
Results. No complications were observed with the implant. Comparing the dose volume histograms, rectal volume achieving 20,
50, and 70Gy (V20, V50 and V70) was, without and with spacer: V20: mean: 86.5% (70–95), 69% (54–84); V50: 51.5% (48–58), 35%
(26–41); V70: 20% (19–21), 11% (9–16), respectively. These data represent a decrease in the dose received by the rectum V20, V50
and V70 of 20.5%, 32.6% and 42.6% respectively. Average dose in rectum with and without implant was: 51.3Gy (48.7–53.9) and
36.5Gy (26.5–43.5) respectively, representing a decrease of 29%. During treatment, rectal toxicity was not observed.
Conclusion. The inﬂatable balloon placement is a safe and effective procedure, which increases the distance prostate–rectum,
allowing decrease radiation dose in the rectum.
http://dx.doi.org/10.1016/j.rpor.2013.03.513
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Introduction. Rectal volume (RV) can change daily due to the state of ﬁlling despite dietary instructions and emptying procedures
with an inﬂuence to the absorbed dose. It has also been suggested a signiﬁcant decrease in RV during Intensity-Modulated
Radiation Therapy (IMRT) for prostate cancer. Tomotherapy would avoid these kinds of situations through daily veriﬁcation with
megavoltage CT (MVCT) and correction if necessary.
Objective. To evaluate RV variations during hypofractionated Image-Guided Radiation Therapy (IGRT) to prostate cancer treatment
using MVCT in the TomoTherapy Hi Art System.
Materials and methods. We have performed a retrospective study of the RV in 30 patients with prostate cancer incorporating
anatomical information provided by daily MVCT scans. The rectum was contoured days 1, 15 and 27 of the treatment, and
reviewed by one of the investigators. We utilized a TomoTherapy treatment planning workstation and the Planned Adaptive
software. The absolute RV was examined to identify deviation between the planned and mean RV. All patients followed dietary
instructions and were treated in a hypofractionated regimen to deliver 70.2Gy in 27 fractions.
Results. A total of 90 scans were contoured. The mean RV in the planning CT scan was 72.02 cc (r: 29.03–128.25). The combined
average deviation of the actual RV from the planned volume was 14.46 cc (range 0.39–87.12). Mean Individual volume for day 1
was 21.77 cc (r: 0.15–142.76), day 15 was 17.68 cc (r: 1.33–79.48), and day 27 was 20.27 cc (r: 1.42–71.12).
Conclusions. We have observed that there is a large rectal motion during hypofractionation in prostate cancer patients even with
rectum emptying procedures. However plans can be adapted based on the image feedback from daily MVCT scans to allow the
actual delivered doses to closely track the original planned doses, no signiﬁcant decrease in RV during helical IGRT was observed.
http://dx.doi.org/10.1016/j.rpor.2013.03.514
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Introduction. In the radiotherapy service of hospital, we started to plan IMRT treatments inMarch 2010. Butwewanted to introduce
some variations in our planning with the aim of improving them, shortening the time of treatment and the waiting of the patient,
but the most important of all, without losing the quality of the treatment.
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Objective. We have compared the two situations: if we had continued with our treatment until wow and when we have changed
the treatment, two years ago.
Material and methods. We have used these material and methods: the planner XIO (VERSION 4.5 and 4.62 of CMS), accelerators
linear siemens, model artiste (MLC 160 sheets, 05 cm nominal width) and IMRT of step and shoot. The proposed method consists
of carrying out a comparison of two planning prostates. We recalculate IMRTS’s planning of the year 2010 in 2012, with many
experience acquired during these years, have managed to diminish the number of segments, the time of radiation and all this
without losing the quality of the treatment. To improve the ﬁnal results, we modiﬁed the parameters during the calculation. To
improve our ﬁnal result, we modiﬁed the parameters with the aim to reduce segments without the histogram.
Results. The modiﬁcations of the parameters in the calculation have considerably reduced the 269 segments in the treatment
from 2010 to 69 segments in 2012.
Conclusion. The analysis of the registered information has shown a reduction in the number of segments without altering the
treatment dosimetric quality.
http://dx.doi.org/10.1016/j.rpor.2013.03.515
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Background. In the treatment of early prostate cancer, clinical data suggest that higher radiation doses delivered to the bulb of
penis and proximal penile structures correlates with higher rates of post-radiation impotence. Is of special interest irradiation
techniques that reduce the dose in the tissues.
Objectives. Review sexual impotence in patients treated with radical technical VMAT-Rapid Arc (IGRT/CBCT daily) and relationship
with the radiation doses to the penile bulb.
Methods. We conducted this study in a consecutive series of 16 patients diagnosed for localized prostate cancer (low risk and
intermediate risk without androgen deprivation) treated between May 2011 and December 2012. All patients were treated with
volumetric modulated arc therapy (VMAT). Dose prescription was 70Gy to a planning target volume (2.5Gy/fraction). The Impo-
tence Status was assessed pretreatment and at the last follow-up. Was measured at the median dose to the bulb (MD) for all
patients, being located by CT fusion with MRI in all patients. The dose limiting established for performing dosimetry was DM to
bulb < of 47.5Gy.
Results. 16 patients were included. 13 of the 16 patients were potent before the treatment. 3 were impotent and were excluded.
Mean follow-up was 11 months (4–16). Only 2 patients of 13 were impotent post-radiation, without other known causes. MD to
the bulb was 2642.8 cGy on the potent men and 5069.5 cGy on the impotent men.
Conclusions. VMAT-Rapid Arc provides treatment plans with high conformity is an efﬁcient radiotherapy technique to increase
dose in target volumesanddecrease irradiationdose in organs at risk. The technique is very important tomaximizeposttreatment
potency. Our data conﬁrm this.
http://dx.doi.org/10.1016/j.rpor.2013.03.516
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Introduction. Recommended treatment guidelines for localized prostate cancer by most urologists and radiation oncologists in
Spain, include surgery or radiotherapy. However, there are patients who refuse treatment or are not considered candidates
for local treatment due to comorbidities or advanced age, being treated with androgen deprivation monotherapy. Objective. To
retrospectively analyze our experience in patients diagnosed with localized castrate resistant prostate cancer who underwent
external beam radiotherapy.
Method. Between March 2006 and July 2011, 13 patients attended our center with a diagnosis of castrate resistant prostate cancer.
Staging workup was negative. No patient received chemotherapy previously. Initially 2, 4 and 6 patients were classiﬁed as low,
intermediate and high risk, respectively, according to risk groups by D’Amico. All patients received 3D radiation therapy and
continued androgen deprivation during the treatment.
Results. From 2006 to 2011 we treated 13 patients. Median PSA level before radiation therapy was 4.8ng/ml (2.6–64ng/ml). Median
Total radiation dose was 72Gy (66–78Gy). With a median follow-up of 49 months (12–55 months), PSA response after treatment
occurred in 8 patients (67%) with a median time to biochemical progression of 18.6 months. Distal failure was the most frequent
clinical failure. Any local failure was detected.
